P1, N=50, Not yet recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

P1, N=22, Active, not recruiting, Agenus Inc. | Recruiting --> Active, not recruiting | N=98 --> 22

P1, N=60, Recruiting, UroGen Pharma Ltd. | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025

P2, N=36, Recruiting, Weill Medical College of Cornell University | Active, not recruiting --> Recruiting | N=12 --> 36 | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: May 2024 --> May 2025

P2, N=4, Terminated, The University of Texas Health Science Center at San Antonio | Active, not recruiting --> Terminated; PI left the institution

P2, N=150, Recruiting, Prisma Health-Upstate | Trial completion date: Dec 2026 --> Jun 2027 | Trial primary completion date: Jun 2025 --> Feb 2026

P3, N=124, Not yet recruiting, Centre Leon Berard

P1, N=67, Active, not recruiting, Agenus Inc. | Recruiting --> Active, not recruiting | N=200 --> 67

P1, N=15, Not yet recruiting, University of Southern California

P2, N=0, Withdrawn, Agenus Inc. | N=177 --> 0 | Recruiting --> Withdrawn

P2, N=24, Recruiting, Weill Medical College of Cornell University | Not yet recruiting --> Recruiting

P2, N=230, Active, not recruiting, Agenus Inc. | Trial primary completion date: Jan 2024 --> Feb 2025

P2, N=45, Not yet recruiting, Immune Oncology Research Institute

P2, N=24, Not yet recruiting, Weill Medical College of Cornell University

P2/3, N=92, Recruiting, The Netherlands Cancer Institute

P2, N=15, Not yet recruiting, Nicholas DeVito, MD

P1/2, N=130, Recruiting, Anaveon AG | Trial primary completion date: Jun 2024 --> Sep 2024

P1, N=15, Recruiting, Chinese PLA General Hospital | N=10 --> 15

Overall, QL1706 plus chemotherapy, regardless of having bevacizumab, was generally tolerable and had promising antitumor activity for EGFR wild-type advanced NSCLC in first-line setting. Moreover, QL1706 plus chemotherapy and bevacizumab showed favorable antitumor activity for patients who had EGFR mutated NSCLC but failed in TKI therapy, demonstrating a potential for treating this population.

P2, N=220, Suspended, Agenus Inc. | Trial completion date: Oct 2023 --> May 2028 | Recruiting --> Suspended | Trial primary completion date: Oct 2023 --> May 2028

P2, N=25, Recruiting, Northwestern University | Not yet recruiting --> Recruiting

Here, we probe the decline of B cells in human CTLA-4 knock-in mice by using anti-human CTLA-4 antibody Ipilimumab conjugated to a drug payload emtansine (Anti-CTLA-4 ADC)...B cell depletion is mediated by both CD4 and CD8 T cells and at least partially rescued by anti-TNF-alpha antibody. These data revealed an unexpected antagonism between T and B cells and the importance of regulatory T cells in preserving B cells.

P2, N=28, Recruiting, University of Colorado, Denver | Trial completion date: Nov 2024 --> Nov 2025 | Trial primary completion date: Nov 2023 --> Nov 2024

P2, N=230, Active, not recruiting, Agenus Inc. | Recruiting --> Active, not recruiting

P2, N=12, Active, not recruiting, Weill Medical College of Cornell University | Recruiting --> Active, not recruiting

P1/2, N=27, Terminated, Turnstone Biologics, Corp. | Trial completion date: Dec 2023 --> Jan 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2023 --> Jan 2023; Sponsor decision

P2, N=25, Not yet recruiting, Northwestern University | Phase classification: P=N/A --> P2

Next-generation anti-CTLA-4 antibodies, such as botensilimab, are showing promise in clinical trials. Combining botensilimab with RT and/or CD40 agonist may offer additional benefits for challenging tumor types.

P1, N=30, Not yet recruiting, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

P1, N=12, Not yet recruiting, HonorHealth Research Institute

Anti-PD-1 antibody monotherapy might be less effective against large NSCLC due to the infiltration of Treg cells. Therefore, it might be appropriate for large NSCLC to select a treatment including an anti-CTLA-4 antibody, which can target Treg cells.

P1/2, N=30, Active, not recruiting, Hatim Husain | Recruiting --> Active, not recruiting

P1/2, N=63, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting

Recently, immune checkpoint inhibitor (ICI) based combination therapies, including anti-PD-1 antibody, nivolumab with anti-CTLA-4 antibody, and ipilimumab have become the primary treatment option for metastatic or unresectable renal cell carcinoma (RCC). Our microbiome analysis revealed that the proportion of Lactobacilli was significantly increased by B. longum 420. Although the detailed mechanism of action is unknown, it is possible that microbiome alteration by B. longum 420 enhances the efficacy of the ICIs.

This pharmacovigilance study detected several safety signals not listed on the drug label of tremelimumab. The results help clinicians manage patients on tremelimumab therapy.; Public health; Endoscopy and interventional pulmonology; Cell and molecular biology; General respiratory patient care; Respiratory intensive care; Epidemiology; Surgery

P1, N=29, Terminated, Alpine Immune Sciences, Inc. | Trial completion date: Dec 2024 --> Feb 2023 | Active, not recruiting --> Terminated; Sponsor decision

P1, N=62, Terminated, Alpine Immune Sciences, Inc. | Trial completion date: Dec 2024 --> Feb 2023 | Active, not recruiting --> Terminated; Sponsor decision

No abstract available

P1, N=450, Recruiting, Agenus Inc. | N=195 --> 450

Recombinant IL-2 (proleukin) induces durable responses in approximately 10% of patients with melanoma...In Part 3, the efficacy and safety of ANV419 in combination with the approved doses pembrolizumab or ipilimumab will be evaluated using a Simon’s 2-stage design...Preliminary monotherapy efficacy data are expected by Q1/2024. Clinical trial information: NCT05578872.

MCA-205 tumors were generated in C57BL/6 mice and were treated with DOX, anti-PD1 (RMP1-14), anti-CTLA4 (9D9 mouse IgG2b) or a mouse surrogate of botensilimab, an anti-CTLA4 (9D9 mouse IgG2b.DLE) antibody with enhanced binding to FcγR, or combination DOX plus anti-PD-1/CTLA-4. Pathway analysis from bulk RNA sequencing demonstrated upregulation of T cell activation in DOX/PD-1/CTLA-4 tumors compared to control tumors. Further work will correlate these findings with human STS patients receiving DOX plus CTLA-4/PD-1 blockade in an ongoing clinical trial (NCT04028063).

P1/2, N=86, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Initiation date: Apr 2023 --> Jul 2023